JP2008007485A - Dead body fluid leakage-preventing agent - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a dead body fluid leakage-preventing agent which can quickly absorb a body fluid and can then be swollen and solidified to effectively prevent the leakage of the body fluid, when injected and charged in the coeloms of the dead body with an injector and then brought into contact with the body fluid in the coeloms. <P>SOLUTION: This dead body fluid leakage-preventing agent is characterized by dispersing highly water-absorbing resin powder (D) in a viscous liquid substrate comprising at least one solvent (A) selected from the group consisting of hydrophilic ethers and esters, and at least one dispersion stabilizer (B) selected from the group consisting of polyalkylene oxide-based thermoplastic nonionic type water-absorbing resins, acrylic acid copolymer carboxy vinyl polymers, acrylic acid copolymer carboxy vinyl polymer/alkali-neutralizing agents, lipophilic smectite, synthetic hectorite, natural hectorite, and bentonite, and/or a thickener (C) such as urethane resin, polyvinyl ether, ethyl cellulose, or polyethylene oxide. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

  The present invention relates to an oil jelly-like body fluid leakage preventing agent for preventing fluid leakage from a corpse by loading and sealing the body cavity such as mouth, nose, ear, anus, and female vagina.

  In general, after death of a human or animal, muscles in various parts of the body cavity are relaxed, and body fluids such as gastric fluid, lung fluid, ascites, and excreta are often leaked, causing malodor and infection by pathogenic bacteria. For this reason, for example, in hospitals, after confirming death, a large amount of gauze, absorbent cotton, etc. are loaded into body cavities such as the mouth, nose, ears, anus, and female vagina to prevent leakage of bodily fluids. Similar measures are also taken for the opening of the body after an accident or surgery. However, many of the operations for loading gauze, absorbent cotton, etc. into the body cavity are often performed by the hands of employees and nurses, etc., and at the same time the gauze, absorbent cotton, etc. have low water absorption capacity Therefore, there is a problem that body fluid often leaks during or after work, and there is a possibility of post-mortem infection due to this leaked substance during work, and there has been a strong demand for a solution.

  For this reason, it is known that high water-absorbent resin powder is loaded into the mouth, nose, ears, throat, etc. instead of gauze, absorbent cotton, etc. A method of loading a water-absorbent resin powder (see Patent Document 1), or a method of using a water-absorbent resin powder containing stabilized chlorine dioxide wrapped in a water-soluble sheet in the ear throat and nostril while the powder remains in the throat. Patent Document 2) is known. However, even if such a superabsorbent resin powder is to be loaded, it is difficult to load a narrow body cavity such as the throat and anus because of poor fluidity. Moreover, if it is only the entrance part of a nostril or an ear canal, such fine powder can be filled with an injector like a syringe, but it cannot be filled to the back. Also, if you try to fill while moving the injector to fill the depths, the fine powder that comes out of the tip will scatter and only dirty around the body.

  In recent years, it has been proposed to use jelly instead of powder in order to solve problems such as poor filling properties and workability of such a highly water-absorbent resin powder and scattering. A method using a powdered polymer dissolved in an appropriate amount of water and mixed appropriately to form a jelly (see Patent Document 3), or a method using an amphiphilic gel containing dimethylacrylamide as a main component (Patent Document 4) And a method using a high-water-absorbing polymer powder dispersed in a jelly containing alcohol as a main component (see Patent Document 5).

  A filling method for filling such a jelly-like body fluid leakage preventing agent in, for example, the throat of the nostril will be described with reference to FIG. 1. As described in Patent Document 5, a jelly-like body fluid leakage prevention agent is described. The injector 1 in which the agent 2 is accommodated has a piston 3 slidably inserted from the rear end thereof, and has an injection port 4 covered with a protective cap 5 at its tip, and is a film pack (not shown). ) Wrapped and sealed. The insertion tube 6 to be inserted into a body cavity such as the throat B has a connection portion 7 connected to the injection port 4 of the injector 1 at one end and an opening portion 8 inserted into the nostril A at the other end.

  Next, a method for using the corpse treatment apparatus prepared in this way will be described. In FIG. 1, A is a nostril, B is a throat part, C is a tongue, D is a trachea, E is an esophagus. At the time of use, the injector 1 is taken out from the film pack, the protective cap 5 of the inlet 4 of the injector 1 is removed, and the connecting portion 7 of the insertion tube 6 is fitted to the inlet 4 to connect the insertion tube 6. Next, the opening 8 of the insertion tube 6 is inserted from the nostril A toward the throat B, and the insertion is stopped when the stopper portion 9 of the insertion tube 6 hits the nose tip B. Then, the piston 3 of the injector 1 is pressed, and the jelly-like body fluid leakage preventing agent 2 in the injector 1 is injected into the throat B through the insertion tube 6. After the body fluid leakage preventing agent 2 in the injector 1 is extruded and filled, the injector 1 and the insertion tube 6 are removed from the nostril A.

The jelly-like body fluid leakage preventing agent as described above has a high fluidity and is easily filled even in a narrow body cavity such as a nostril or an ear canal, and has an advantage that it does not scatter even if it is press-fitted with an injector. In particular, in the case of a jelly in which a large number of highly water-absorbing polymer powders are dispersed, the water-absorbing performance is high, and it is possible to prevent the polymer from absorbing body fluid leaking from the body cavity and leaking to the outside. However, the conventional jelly-like body fluid leakage prevention agent is a jelly-like product added with a gelling agent to water or alcohol, so the liquid absorption rate after injecting and loading into the body cavity with an infusion device is slow, so There is a problem that body fluid is likely to leak due to relaxation of muscles in each part of the body cavity after death. Moreover, it cannot be said that it is sufficient in terms of the ability to absorb liquid immediately after injection / loading into a body cavity, and there is room for improvement in terms of the stability of stably maintaining the jelly shape for a long period of time.
JP-A-10-298001 (Claims) JP-A-7-265367 (Claims) JP-A-8-133901 (Claims) JP 2001-288002 A (Claims) Japanese Patent No. 3586207 (Claims)

Therefore, the basic object of the present invention is to quickly absorb and swell and solidify body fluid when it is injected and loaded into a body cavity of a corpse with an infusion device and then comes into contact with the body fluid in the body cavity, thereby effectively preventing body fluid leakage. The object is to provide an agent for preventing body fluid leakage.
Furthermore, an object of the present invention is to provide a body fluid leakage preventive agent for a corpse that can be easily prepared into a jelly shape having appropriate fluidity and viscoelasticity that can be injected and loaded into the body cavity of the corpse with good workability, and that can maintain its state stably. Is to provide.

  In order to achieve the above object, according to the present invention, at least one solvent (A) selected from the group consisting of hydrophilic ethers and esters, a polyalkylene oxide-based thermoplastic nonionic water-absorbing resin, At least one selected from the group consisting of carboxyvinyl polymer of acrylic acid copolymer, carboxyvinyl polymer of acrylic acid copolymer / alkali neutralizer, lipophilic smectite, synthetic hectorite, natural hectorite, and bentonite Body fluid leakage, characterized in that superabsorbent resin powder (D) is dispersed in a viscous liquid base containing seed dispersion stabilizer (B) and / or thickener (C) An inhibitor is provided.

In a preferred embodiment, the solvent (A) is at least one selected from the group consisting of polyoxyethylene dimethyl ether and polyoxyethylene fatty acid diester.
In another preferred embodiment, the dispersion stabilizer (B) is a polyalkylene oxide thermoplastic nonionic water-absorbing resin.
In still another preferred embodiment, the thickener (C) is at least one selected from the group consisting of urethane resin, polyvinyl ether, ethyl cellulose, and polyethylene oxide.
In a particularly preferred embodiment, the polyalkylene oxide-based thermoplastic nonionic water-absorbing resin as the dispersion stabilizer (B), urethane resin, polyvinyl methyl ether, ethyl cellulose and polyethylene oxide containing 45 to 50% ethoxy group A mixed system with at least one thickener (C) is used.
The body fluid leakage preventing agent of the present invention is at least one selected from the group consisting of a liquid nonionic surfactant (E) that generates heat when mixed with water and an alcohol-based organic solvent (F) soluble in water. It can also contain seeds, and can also contain at least one selected from the group consisting of bactericides, fungicides / preservatives, deodorants and fragrances.

  The body fluid leakage preventive agent of the present invention comprises at least one solvent (A) selected from the group consisting of hydrophilic ethers and esters, a polyalkylene oxide-based thermoplastic nonionic water-absorbing resin, acrylic acid Copolymer carboxyvinyl polymer, acrylic acid copolymer carboxyvinyl polymer / alkali neutralizer, lipophilic smectite, synthetic hectorite, natural hectorite, and at least one dispersion selected from bentonite The superabsorbent resin powder (D) is dispersed in a viscous liquid base containing a stabilizer (B) and / or a thickener (C) such as a urethane resin, polyvinyl ether, ethyl cellulose, or polyethylene oxide. Because it is an oil jelly-like product, it can be quickly injected into the body cavity of an corpse with an infusion device and contacted with body fluids in the body cavity. Absorb body fluids, swelling to cause to solidify the flowable no hard jelly (solid gel), whereby it is possible to perform anti fluid leakage effectively.

  According to a preferred aspect of the body fluid leakage preventive agent of the present invention, the solvent (A) is at least one selected from the group consisting of polyoxyethylene dimethyl ether and polyoxyethylene fatty acid diester. A polyalkylene oxide-based thermoplastic nonionic water-absorbing resin which can be easily prepared into a jelly shape having an appropriate fluidity and viscoelasticity that can be injected and loaded into a body cavity with good workability, and as the dispersion stabilizer (B) And a mixture of at least one selected from the group consisting of urethane resin, polyvinyl ether, ethyl cellulose and polyethylene oxide as the thickener (C), so that the superabsorbent resin when in contact with body fluids The uniform dispersion state of the powder (D) can be more reliably maintained. Therefore, the superabsorbent resin powder (D) is dispersed in a viscous liquid base containing a combination of the solvent (A) and the dispersion stabilizer (B) and / or the thickener (C). The fluid leakage preventive agent can stably maintain a jelly-like state with adequate fluidity and viscoelasticity that can be injected and loaded into the body cavity of the corpse with good workability. The body fluid can be quickly absorbed and swollen to solidify into a solid jelly having no fluidity, thereby preventing body fluid leakage more effectively.

  The body fluid leakage preventing agent of the present invention further comprises at least one of a liquid nonionic surfactant (E) that generates heat when mixed with water and an alcohol-based organic solvent (F) soluble in water as an auxiliary solvent. By containing, viscosity adjustment becomes easy, fluidity can be improved, and even a narrow body cavity such as the throat can be injected and loaded more smoothly. In particular, when it contains a liquid nonionic surfactant (E) that is soluble in water and rapidly dissolves when mixed with water, the nonionic surfactant (E) generates heat when it comes into contact with body fluid. The liquid absorption speed of the highly water absorbent resin powder (D) can be increased. Furthermore, by containing at least one selected from the group consisting of bactericides, fungicides / antiseptics, deodorants and fragrances, these desired effects can also be exhibited.

  As a result of earnest research to solve the above-described conventional problems, the present inventor has found that at least one solvent (A) selected from the group consisting of hydrophilic ethers and esters, and the specific solvent dissolved therein An oil jelly-like body fluid leakage preventing agent obtained by dispersing a superabsorbent resin powder (D) in a viscous liquid base containing a dispersion stabilizer (B) and / or a thickener (C) The present inventors have found that when a body cavity is injected and loaded, the body fluid is quickly absorbed and swollen to solidify into a solid jelly having no fluidity, and the present invention has been completed. The reason why such an effect is obtained is not necessarily clear, but at least one solvent (A) selected from the group consisting of hydrophilic ethers and esters is also used as a solvent for cleaning agents. As described above, it is considered that it is hydrophilic and also excellent in the solubility of fats and oils, and therefore has an excellent affinity with body fluids of corpses containing not only moisture but also fats and oils. Moreover, since it is also oleophilic, it is possible to disperse the superabsorbent resin powder (D) in a relatively large amount, and in the solvent (A), the specific dispersion stabilizer (B) and / or The oil jelly-like body fluid leakage preventing agent of the present invention obtained by dispersing the superabsorbent resin powder (D) in a viscous liquid base in which the thickener (C) is dissolved is also excellent in stability.

Hereinafter, each component of the bodily fluid leakage preventing agent of the present invention will be described.
First, as the at least one solvent (A) selected from the group consisting of hydrophilic ethers and esters, among ethers and esters, if they are liquid compounds at room temperature (20 ± 5 ° C.) showing hydrophilicity, In particular, at least one selected from the group consisting of polyoxyethylene dimethyl ether and polyoxyethylene fatty acid diesters can be preferably used. The polyoxyethylene fatty acid diester is represented by the general formula RCOO (CH ₂ CH ₂ O) _n COR, and the alkyl group R preferably has 17 or less carbon atoms, and examples thereof include polyethylene glycol dilaurate and polyethylene glycol dioleate. . Among these, polyoxyethylene dimethyl ether is particularly preferable. The degree of polymerization of these solvents is not particularly limited as long as the degree of polymerization becomes liquid at room temperature (20 ± 5 ° C.).
However, since these solvents (A) are in a smooth liquid state at room temperature, it is necessary to dissolve the dispersion stabilizer (B) and / or the thickener (C) to increase the viscosity of the composition. When the dispersion stabilizer (B) and / or the thickener (C) is not added, when the obtained body fluid leakage preventing agent is pressed into the body cavity by the injector, the solvent comes out first from the tip of the injector. As a result, the solid content tends to clog the injector tip, making it difficult to inject.

  The content of the solvent (A) is preferably about 30 to 85% by mass, more preferably about 40 to 80% by mass, and further preferably about 50 to 70% by mass of the total amount of the body fluid leakage preventing agent. When the content of the solvent (A) exceeds 85% by mass, there is no problem in the dispersibility of the superabsorbent resin powder, but it is difficult to form a jelly and is not preferable because it becomes close to a solution. . On the other hand, if the content of the solvent (A) is too low, it is difficult to obtain a good jelly state.

  The dispersion stabilizer (B) used in the present invention is for maintaining a uniform dispersion state of the superabsorbent resin powder, can absorb various electrolyte aqueous solutions, and is hardly affected by the electrolyte concentration. Oxide-based thermoplastic nonionic water-absorbent resin, carboxyvinyl polymer of acrylic acid copolymer, carboxyvinyl polymer / alkali neutralizer of acrylic acid copolymer, lipophilic smectite, synthetic hectorite, natural hectorite, And at least one selected from the group consisting of bentonite is used. Among these dispersion stabilizers (B), a polyalkylene oxide-based thermoplastic nonionic water-absorbing resin is preferable, and this resin can absorb various aqueous electrolyte solutions and is hardly affected by the electrolyte concentration. Absorption of alkaline aqueous solution is possible. However, when only this resin is used as a dispersion stabilizer, the resulting jelly-like product tends to be somewhat hard, and there is a slight difficulty in terms of slipping properties at the time of injection. Mixing of an alkylene oxide-based thermoplastic nonionic water-absorbing resin with at least one thickener (C) selected from urethane resin, polyvinyl methyl ether, ethyl cellulose containing 45 to 50% ethoxy groups, and polyethylene oxide A system is preferred.

  The content of the dispersion stabilizer (B) is preferably about 0.5 to 40% by mass, more preferably about 1 to 30% by mass, based on the total amount of the body fluid leakage preventing agent. If the content of the dispersion stabilizer (B) is too low, it becomes difficult to maintain the uniform dispersibility of the superabsorbent resin powder. On the other hand, even if it is added in a large amount exceeding 40% by mass, the effect is further improved. Is not preferable from the viewpoint of economy.

  The said thickener (C) is added in order to raise the viscosity of a composition and to make it a stable oil jelly-like thing. The thickener (C) is not limited to a specific one, but includes a urethane resin, polyvinyl ether, ethyl cellulose, polyethylene oxide, sodium carboxymethyl cellulose, carboxymethyl cellulose, methyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, sora gum, and sodium alginate. At least one thickener selected from the group can be suitably used. Among these, urethane resin, polyvinyl ether, ethyl cellulose, and polyethylene oxide are preferable. The content of the thickener is preferably about 0.1 to 10% by mass, more preferably about 0.2 to 7% by mass, based on the total amount of the body fluid leakage preventing agent.

  As the superabsorbent resin powder (D) used in the present invention, conventionally known superabsorbent resin powders can be used and are not limited to specific ones. Among them, polyvinyl acrylate, polyacrylic Acid salt, alginate, crosslinked acrylic acid graft copolymer, copolymer of vinyl alcohol and polyacrylic acid, polyethylene glycol polymer, polyacrylamide resin, copolymer of polyacrylic maleic acid, polyethylene oxide polymer , And at least one selected from the group consisting of polyalginate-based polymers can be suitably used.

The superabsorbent resin powder (D) is preferably a powder having an average particle size of about 18 mesh to 160 mesh (in terms of Tyler), more preferably about 30 mesh to 140 mesh.
Further, the content of the superabsorbent resin powder (D) must be a necessary amount to immediately absorb and expand the body fluid from the body without leaking from the body cavity to create a non-flowable gel. The content of the superabsorbent resin powder is preferably about 5 to 50% by mass, more preferably about 15 to 35% by mass, based on the total amount of the body fluid leakage preventing agent.

  The body fluid leakage preventive agent of the present invention, in addition to the above-mentioned components, as necessary, becomes a non-solvent surfactant (E) and / or water that generates heat when mixed with water as an auxiliary solvent and is mixed with water. A soluble alcohol-based organic solvent (F) can also be contained.

  Nonionic surfactants (E) that generate heat when mixed with water used in the present invention and are liquid at room temperature include coconut oil fatty acid monoethanolamide, coconut oil fatty acid diethanolamide 1: 1 type, coconut oil fatty acid diethanolamide 1: Type 2, polyoxyethylene coconut oil fatty acid monoethanolamide, lauric acid diethanolamide, polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene higher alcohol ether, polyethylene glycol (average molecular weight of polymerization degree is 600 or less) , Polyoxyethylene polyoxypropylene glycol (pluronic type nonionic surfactant obtained by adding ethylene oxide to polypropylene glycol), polyoxyethylene alkyl (alkyl group having 12 to 14 carbon atoms) ether (ethylene Examples include surfactants such as polyoxyethylene alkyl ether series, sorbitan fatty acid ester series, polyoxyethylene sorbitan fatty acid ester series, etc., such as the number of moles of oxide added: 7 to 12 moles. They can be used in combination. Among these nonionic surfactants (E), liquid polyethylene glycol (average molecular weight of polymerization degree is about 200 to 600) is preferable.

  These liquid nonionic surfactants (E), particularly liquid polyethylene glycol (average molecular weight of the degree of polymerization of about 200 to 600) can be used as a part of the solvent, and the above-mentioned dispersion stabilizer (B) In particular, the polyalkylene oxide-based thermoplastic nonionic water-absorbent resin powder can be easily dissolved at a low temperature (about 30 ° C. to 50 ° C.), and is apparent from Test Example 2 described below when mixed with water. As mentioned above, when it comes into contact with water, it generates heat and the water temperature rises (increase by about 10 ° C to 12 ° C), and since it is a surfactant, it is well compatible with water and easily mixed and dissolved with water. In addition, the water absorption rate of the highly water-absorbent resin can be increased and solidified quickly into a solid jelly having no fluidity to prevent leakage of body fluid.

  That is, in general, the water absorption rate of the highly water-absorbent resin powder (D) tends to increase as the temperature rises. Therefore, due to the exothermic action of the nonionic surfactant (E) when in contact with body fluid, The liquid absorption speed of the water absorbent resin powder (D) can be increased, and the body fluid can be quickly absorbed and swollen to be solidified into a solid jelly having no fluidity. However, as the liquid absorption rate increases, the surface portion of the injected jelly-like material that comes into contact with the body fluid quickly solidifies into a solid jelly with no fluidity, so that the highly water-absorbent resin powder (D) is uniformly dispersed. Tends to collapse. Moreover, when the obtained jelly-like body fluid leakage preventing agent is allowed to stand for a long time, it becomes easy to separate. In the bodily fluid leakage preventing agent of the present invention, the above-mentioned specific dispersion stabilizer (B) that can absorb various electrolyte aqueous solutions and is hardly affected by the electrolyte concentration is further dissolved in the viscous liquid base to obtain a high water absorption. In view of the above, the content of the nonionic surfactant (E) is about 50% by mass or less of the total amount of the body fluid leakage preventing agent. More preferably, it is about 3-40 mass%, More preferably, it is about 5-20 mass%.

The bodily fluid leakage preventive agent of the present invention can contain an anionic surfactant as needed in a quantitative ratio that does not impair the effects of the present invention, in addition to the nonionic surfactant (E). .
Examples of the anionic surfactant include polyoxyethylene alkyl ether sulfate, polyoxyethylene lauryl ether sodium sulfate, polyoxyethylene lauryl ether sulfate triethanolamine, polyoxyethylene alkyl (alkyl group having 11 to 15 carbon atoms) ether. Alkyl ether sulfates such as sodium sulfate (addition moles of ethylene oxide: 3) alkyl (carbon groups of alkyl groups 11, 13, 15) triethanolamine, sodium alkylsulfate, alkylsulfuric triethanolamine, higher alcohol sodium sulfate; Polyoxyethylene alkyl sulfosuccinate disodium, polyoxyethylene sulfosuccinate, polyoxyethylene sulfosuccinate disodium lauryl sulfonate, disodium lauryl sulfonate, sulfoco Surfactants such as sulfosuccinates such as polyoxyethylene lauryl ethanolamide disodium succinate; alkylbenzene sulfonates such as sodium dodecylbenzene sulfonate, and the like are used alone or in combination of two or more. Can do.

As the alcohol-based organic solvent (F), any of the nonionic surfactants or polar solvents that are soluble in water can be used, and are not limited to specific solvents, but include ethylene glycol, propylene glycol, diethylene glycol, and triethylene glycol. At least one alcohol-based organic solvent selected from the group consisting of glycerin, methyl alcohol, ethyl alcohol, and isopropyl alcohol can be suitably used. Among these alcohol solvents, glycerin is preferable. Glycerol easily mixes with water, but slightly increases the water temperature (about 3 ° C.) during mixing. Therefore, it is possible to increase the water absorption rate of the highly water-absorbent resin, increase the viscosity of the prepared body fluid leakage preventing agent, improve the fluidity, and contribute to preventing the oil jelly from coagulating at low temperatures.
The content of the alcohol-based organic solvent is preferably about 20% by mass or less, more preferably about 1 to 10% by mass, based on the total amount of the body fluid leakage preventing agent.

The body fluid leakage preventive agent of the present invention can further contain at least one of other additives such as bactericides, fungicides / preservatives, deodorants, and fragrances, if necessary.
Disinfectants include isopropylmethylphenol, chlorhexidine gluconate, thymol, o-phenylphenol, benzalkonium chloride, cetylpyridinium chloride, benzethonium chloride, triclosan, ε-polylysine, lysozyme chloride, hinokitiol, grapefruit seed extract, mustard extract A thing "Wasaolo" etc. are mentioned, These can be used individually or in combination of 2 or more types.

  Examples of the fungicides and preservatives include sodium paraoxybenzoate, butyl paraoxybenzoate, propyl paraoxybenzoate, isobutyl paraoxybenzoate, sodium benzoate, sodium propionate, thiabendazole, isothiazolone, etc. A combination of more than one species can be used.

  Deodorants include Moso bamboo extract, green tea extract, long-chain betaine compound, deodorant based on the generic type tannin of persimmon extract, plant-type special deodorant mixed with several plant extracts, etc. These can be used alone or in combination of two or more.

  Examples of the fragrances include various natural and artificial fragrances such as floral, citrus, fruity, woody, fresh note, mixed flavor, green and mint.

  The content of the fungicide, fungicide / preservative, deodorant and fragrance as described above maintains the desired effect of each component, and from the viewpoint of obtaining safety and good economic efficiency, the viscosity and fluidity are improved. The proportion of the whole body fluid leakage preventing agent is preferably about 0.001 to 15% by mass, more preferably about 0.003 to 8% by mass for the fungicide and the antifungal preservative, respectively. Similarly, the deodorant is preferably about 0.05 to 20% by mass, more preferably about 0.1 to 10% by mass. Moreover, it is preferable that a fragrance | flavor is about 0.001-10 mass%, More preferably, it is 0.01-5 mass%. In addition, it is also possible to add and contain a pigment, and it is not particularly limited, such as selection of the blending amount and color tone, and can be arbitrarily set.

The viscosity of the body fluid leakage preventive agent of the present invention containing the above components is preferably about 6,000 to 50,000 cPs, more preferably about 10,000 to 40 in order to have good fluidity. , 000 cPs.
In addition, the viscosity here uses a viscometer (manufactured by Brookfield, USA, “Digital Viscometer” model: DV-1 +), spindle No. Although it is the value measured on the measurement conditions of 07, rotation speed: 20rpm, use body fluid leakage prevention agent temperature: 20 degreeC, it is not limited to this, What is necessary is just the measurement value measured on the same conditions.
In addition, as the content of the solvent (A) or the nonionic surfactant (E) is lowered, and accordingly, the content of the superabsorbent resin powder (D) is increased, the time required for the bodily fluid leakage preventing agent to be jelly-like is Since the liquid becomes shorter and the viscosity of the liquid rises, it is possible to adjust the liquid viscosity according to the time of jelly-form and the desired application (application site) by adjusting the amount of these compounds.

  The amount of the body fluid leakage preventing agent of the present invention injected and filled into the body cavity can be appropriately set according to the application site, and is not particularly limited. In addition, depending on the water absorption performance of the superabsorbent resin contained in the oil jelly-like body fluid leakage preventing agent, 3,000 ml of water is gelled and has a water absorption capability to prevent leakage of body fluid from inside the body cavity. It may be to some extent, generally 5 to 60 g is preferable, and more preferably 10 to 40 g. For example, the filling amount of the bodily fluid leakage preventive agent (containing 5 to 50% by mass of the superabsorbent resin) to be injected into the throat from the nostril of the corpse is preferably about 8 to 40 g, more preferably about 10 to 25 g. When the injection amount of the oil jelly-like body fluid leakage preventing agent is too large, the injection device becomes large, so that it is difficult to handle and the cost increases. On the other hand, when the injection amount is too small, it is difficult to harden the body fluid in a gel state, and there is a risk that the body fluid leaks, which is not preferable.

Hereinafter, specific examples of each aspect of a corpse treatment apparatus suitable for injection of the bodily fluid leakage preventing agent of the present invention will be described with reference to the accompanying drawings.
2 to 5 show a treatment apparatus for injecting and loading the body fluid leakage preventing agent into the throat by inserting from the nostril. FIGS. 2 to 4 show the injector 10 and FIG. The pipe | tube 40 is shown and the code | symbol X has shown the bodily fluid leakage prevention agent of this invention accommodated in the injection device 10. FIG.

  2 to 4 show the injector 10, FIG. 4 shows a cross-sectional view of the state rotated by 90 ° around the center line from the state shown in FIG. 2. As shown in FIGS. 2 to 4, the injector 10 includes a cylindrical main body 20 and a piston 30 each made of a plastic such as high-density polyethylene, polyester, and polyamide. The cylindrical main body 20 includes a cylindrical member 21 having a discharge cylinder portion 22 that functions as a discharge port portion at the tip, and a cover member 25 that is crowned on the outer periphery thereof.

  As is clear from FIG. 2, the cover member 25 is a cylinder having an octagonal cross section. The cover member 25 is configured so that a nurse can easily discriminate it from a general syringe in a hospital, and the tip side is slightly tapered. It is formed in a tapered shape so that it does not easily fall off when the cylindrical member 21 is inserted. In addition, it is also possible to make it possible to clearly grasp the application place by coloring the cover member or coloring the cover member so that it is different from the color of other members to form a colorful injector. As clearly shown in FIG. 4, the cover member 25 has a pair of flange portions 26 protruding outward in the radial direction for hooking a finger to the rear end portion. The distal end portion of the collar portion 26 is curved in the direction of the discharge cylinder portion 22 so that the finger can be easily caught. Further, a pair of convex locking portions 23 are formed at the rear end of the cylindrical member 21, and when the collar portion 26 comes into contact with the locking portion 23, a finger is hooked on the collar portion 26 and injected. When the operation is performed, the cover member 25 is configured not to move backward from the rear end of the cylindrical member 21. Moreover, the protective cap 29 is removably crowned at the distal end opening of the discharge cylinder portion 22 after the body fluid leakage preventing agent of the present invention is filled in the injector 10. In this embodiment, the cylindrical member 21 and the cover member 25 are formed separately, but may be integrally formed.

  On the other hand, the piston 30 is slidably inserted into the cylindrical member 21 of the cylindrical main body 20 from the rear end side. The length of the piston 30 is designed to be longer than the length of the cylindrical member 21 so that the whole body fluid leakage preventing agent X of the contents can be pushed out. The piston 30 has a piston rod 31 having a cross-shaped cross section, and a circular flange portion 32 having a diameter slightly larger than the cross-sectional dimension of the piston rod is formed at the tip portion thereof. A gasket 34 made of synthetic resin, rubber or the like is crowned around the flange portion 33 formed so as to protrude from the circular flange portion 32. In addition, a disc-like portion 35 for touching the finger is formed at the rear end of the piston rod 31 so that the piston rod 31 can be easily pressed with the finger. When the piston 30 is inserted into the cylindrical member 21 of the cylindrical main body 20 from the rear end portion side, the piston 34 passes through the cylindrical member 21 with the gasket 34 in contact with the inner peripheral surface of the cylindrical member 21 of the injector 10. It is configured to slide. Further, a ring-shaped ridge portion 24 protruding slightly inward is formed on the inner peripheral surface in the vicinity of the rear end portion of the cylindrical member 21, and the circular flange portion of the piston rod 31 is formed on the ridge portion 24. The piston 30 is configured not to easily come out of the cylindrical main body 20 when it hits 32. In this embodiment, the piston rod 31 has a cross-shaped cross section, but may have a rod shape such as a circular cross section.

  The insertion tube 40 is made of a flexible synthetic resin such as a polyester elastomer, a soft vinyl chloride resin, or a rubber having a flexibility of bending along the shape of the nasal cavity when inserted into the nostril. As shown in FIG. 5, the distal end portion 41 of the insertion tube 40 is formed in a substantially hemispherical shape so as to be easily inserted from the nostril and is closed, and on the side thereof, two positions shifted from each other are perpendicular to each other. In addition to having a pair of opening portions 42 in each direction, a tapered connection portion 43 that is slightly expanded on the rear side for connection to the discharge cylinder portion 22 of the injector 10 is provided at the rear end portion. In addition, a stopper section 44 having a circular cross section protruding outward in the radial direction so as to surround the outer periphery is provided at a position at a predetermined distance from the rear end of the insertion tube 40 (preferably the tip position of the connection portion 43).

  The opening 42 at the distal end of the insertion tube 40 can be a hole having a desired shape such as a circle or an ellipse, and the position is preferably a distance of about 5 to 30 mm from the distal end of the insertion tube. Moreover, although the number of the aperture parts 42 is four in this embodiment, it may be an arbitrary number of about 1 to 6. The stopper portion 44 determines the length (injection position) that the opening portion 42 reaches when the insertion tube main body is inserted into the pharynx through the nostril, but from the distal end of the insertion tube 40 to the stopper portion 44. Is preferably about 100 to 140 mm, and the outer diameter of the insertion tube body is preferably about 3.5 to 7 mm, and the inner diameter is preferably about 2 to 5 mm.

  In the above embodiment, the connection portion 43 is integrally formed at the rear end portion of the insertion tube 40, but the connection portion 43 may be a separate body. In this case, the connecting portion is preferably formed of a rigid synthetic resin, and the connecting portion and the insertion tube main body are joined by an appropriate means such as an adhesive or welding. Moreover, the stopper part 44 may be formed at the front end of the connection part, or may be formed at the rear end of the insertion tube. Furthermore, the insertion tube main body can be bent at a predetermined position from the distal end portion, and can be smoothly inserted without resistance when inserted from the nostril to the back of the pharynx. In this case, the bending position is preferably an arbitrary portion having a distance of about 22 to 45 mm, more preferably about 20 to 30 mm from the distal end of the insertion tube main body, and the bending angle is preferably 0 to 95 °, more preferably. Is 30-70 °.

  When using the corpse treatment apparatus, first, the protective cap 29 of the discharge tube portion 22 of the injector 10 is removed, and the discharge tube portion 22 is fitted into the connection portion 43 of the insert tube 40 to connect the insert tube 40 and the injector 10. Connecting. Next, the insertion tube 40 is inserted from the nostril A (see FIG. 1) toward the throat B, and the insertion is stopped when the stopper portion 44 of the insertion tube 40 hits the tip of the nose. At this time, a lubricant may be applied to the insertion tube 40 in order to reduce the insertion resistance. Then, the piston 30 of the injector 10 is pressed, and the jelly-like body fluid leakage preventing agent X in the injector 10 is injected into the throat B through the insertion tube 40. After the body fluid leakage preventing agent X in the injector 10 is extruded and filled, the injector 10 and the insertion tube 40 are extracted from the nostril A.

  In the above operation method, the insertion tube 40 is inserted into the nostril A while being connected to the injector 10, but the insertion tube 40 is first inserted into the nostril A, and then the injector 10 is connected to the insertion tube 40. Also good. Further, the injector 10 and the insertion tube 40 may be stored in a container in a connected state, and in this case, the treatment work can be performed immediately after being taken out from the container. Alternatively, in the above-described embodiment, the injector 10 and the insertion tube 40 are separate bodies, but they may be integrally manufactured. Further, even if a mark is provided instead of the stopper portion 44 formed on the insertion tube 40, variations in the insertion position can be prevented to some extent.

Next, a preferred embodiment of a treatment apparatus for injecting and loading the body fluid leakage preventing agent into the anus and / or vagina will be described with reference to FIGS.
6 to 8 show the injector 10a. FIG. 8 shows a cross-sectional view of the injector 10a rotated by 90 ° around the center line from the state shown in FIG. As shown in FIGS. 6 to 8, also in this embodiment, the injector 10a includes a cylindrical main body 20a made of a plastic such as high-density polyethylene, polyester, polyamide, etc. And a piston 30. However, unlike the above-described embodiment, a fibrous filler (plug member) Y is housed in the injector 10a together with the jelly-like body fluid leakage preventing agent X. This fibrous filler Y has a gap between the gel in the body cavity of the anus and vagina after the jelly-like body fluid leakage preventing agent X becomes a solid gel, and the muscles in each part of the body cavity relax after death. In order to prevent the body fluid from leaking out even if this occurs, the contents can be limited to the jelly-like body fluid leakage preventing agent X only. The amount of the body fluid leakage preventing agent X (containing 5 to 50% by mass of the superabsorbent resin) contained in one device is about 1 to 10 g, more preferably about 1 to 5 g, and the length of the fibrous filler Y is about It is preferable to set the diameter within a range of 10 to 30 mm and a diameter of about 8 to 23 mm.

  The cylindrical main body 20a includes a cylindrical member 21a having a discharge port portion 22a at the tip, and a cover member 25a covered with an outer periphery thereof. The discharge port portion 22a at the tip of the cylindrical member 21a is formed in a substantially hemispherical shape by a plurality of tongue pieces 28 that are curved and extended outward toward the center in the radial direction. An opening is formed from the opening of the part and a slit between the tongue pieces. Each tongue piece 28 has flexibility so that it can be bent outward. If a cylindrical syringe (syringe) with a large outer diameter is inserted into the anus or vagina after the death until it stiffens, the anal canal and the ostium of the vagina will open widely and it will take time to contract, which may cause fluid leakage. Become. Further, the thinner the cylindrical member 21a, the easier it is to insert and the easier it is to use. Accordingly, the outer diameter of the cylindrical member 21a is preferably set within a range of about 10 to 25 mm, more preferably about 10 to 15 mm, and the inner diameter is set within a range of about 8 to 23 mm.

  As is clear from FIG. 6, the cover member 25a is a cylinder having an octagonal cross section, and is configured so that a nurse can easily distinguish it from a general syringe in a hospital. In addition, it is also possible to make it possible to clearly grasp the application place by coloring the cover member or coloring the cover member so that it is different from the color of other members to form a colorful injector. As clearly shown in FIG. 8, the cover member 25a has a cap-shaped stopper portion 27 that expands rearward at the front end portion thereof, and projects outward in the radial direction for hooking a finger to the rear end portion. The pair of flange portions 26 is provided. The distance from the tip of the cylindrical member 21a to the stopper portion 27 is preferably set within a range of about 15 to 50 mm, and the height of the stopper portion 27 from the outer peripheral surface of the cylindrical member 21a is easily set to the anus or vagina. It is preferable to set within a range of about 5 to 30 mm so as to stop at the mouth. The stopper portion 27 is not necessarily required to have a cap shape as in this embodiment, and a member that can ensure that no further insertion is performed at a position where the injector 10 is inserted into the anus or vagina by a predetermined length. Alternatively, it may be a mark, for example, a disk shape, or a mark that can be easily visually confirmed. Further, the distal end portion of the collar portion 26 is curved in the direction of the discharge port portion 22a so that the finger can be easily caught. It is preferable that the height of the collar portion 26 from the outer peripheral surface of the cylindrical member 21a is set within a range of about 5 to 18 mm, and the degree of curvature of the tip portion is within a range of 0 to 50 °. When such a cover member is used, the above-described collar portion and the stopper portion may be provided at predetermined positions of the cover member. Preferably, as in the present embodiment, the stopper portion is the tip of the cover member or the cover member. When the length is the same as that of the cylindrical member, it is desirable to provide the substantially intermediate portion and the collar portion at the rear end portion of the cover member.

  Further, a pair of convex locking portions 23 are formed at the rear end of the cylindrical member 21a, and when the collar portion 26 comes into contact with the locking portions 23, a finger is hooked on the collar portion 26 and injected. When the operation is performed, the cover member 25a is configured not to move backward from the rear end of the cylindrical member 21a. Further, the protective cap 29a is removably crowned at the tip of the cylindrical member 21a after the injector 10 is filled with the bodily fluid leakage preventing agent of the present invention. Also in this embodiment, the cylindrical member 21a and the cover member 25a are formed separately, but may be integrally formed.

  On the other hand, the structure of the piston 30 is the same as that of the above embodiment, and is slidably inserted into the cylindrical member 21a of the cylindrical main body 20a from the rear end side. The length of the piston 30 is designed to be longer than the length of the cylindrical member 21a so that the body fluid leakage preventing agent X and the fibrous filler Y of the contents can all be pushed out. The piston 30 has a piston rod 31 having a cross-shaped cross section, and a circular flange portion 32 having a diameter slightly larger than the cross-sectional dimension of the piston rod is formed at the tip portion thereof. A gasket 34 made of synthetic resin, rubber or the like is crowned around the flange portion 33 formed so as to protrude from the circular flange portion 32. In addition, a disc-like portion 35 for touching the finger is formed at the rear end of the piston rod 31 so that the piston rod 31 can be easily pressed with the finger.

  When the piston 30 is inserted into the cylindrical member 21a of the cylindrical main body 20 from the rear end side, the piston 30 passes through the cylindrical member 21a with the gasket 34 in contact with the inner peripheral surface of the cylindrical member 21a of the injector 10. It is configured to slide. Furthermore, a ring-shaped ridge 24 protruding slightly inward is formed on the inner peripheral surface in the vicinity of the rear end portion of the cylindrical member 21a, and the circular flange portion of the piston rod 31 is formed on the ridge 24. The piston 30 is configured not to easily come out of the cylindrical main body 20 when it hits 32. In this embodiment, the piston rod 31 has a cross-shaped cross section, but may have a rod shape such as a circular cross section.

  When using the treatment device for injecting and loading the body fluid leakage preventing agent X and the fibrous filler Y into the anus and / or vagina, first, the protective cap 29a of the discharge port 22a of the injector 10a is not removed. For example, it is inserted into the anus or vagina as it is, and the insertion is stopped when the stopper portion 27 hits the outside of the anus or vagina. At this time, a lubricant may be applied to the protective cap 29a in order to reduce insertion resistance. Then, the piston 30 of the injector 10a is pressed, and the jelly-like body fluid leakage preventing agent X and the fibrous filler Y in the injector 10a are injected together with the protective cap 29a. At that time, the superabsorbent resin powder in the bodily fluid leakage preventing agent X that has absorbed the bodily fluid and the liquid in the filth swells, and part of it penetrates into the fibrous filler Y and becomes a solid gel. The body fluid and filth can be effectively prevented from leaking out. Thereafter, the injector 10a is extracted from the anus and vagina.

  The fibrous filler Y is a non-woven fabric of superabsorbent resin fiber, compressed pulp paper, cotton, cotton and superabsorbent resin fiber blend, molded product of superabsorbent resin fiber, synthetic fiber nonwoven fabric, cloth, etc. In particular, Runseal (registered trademark) F or Runseal (registered trademark) K manufactured by Toyobo Co., Ltd., which is composed of an inner layer of water-swellable fiber, for example, an acrylic fiber and an outer layer made of a water-absorbing resin, is formed into a cylindrical shape. It is preferable to use a molded product or a product obtained by compression-molding pulp into a cylindrical shape (eg, a female tampon type).

  A treatment apparatus for injecting and loading a bodily fluid leakage prevention agent into the throat by inserting through the nostril as described above, and a treatment apparatus for injecting and loading the bodily fluid leakage prevention agent into the anus and / or vagina include an ear hole and It is preferable that the body treatment apparatus unit is configured to be housed in one container together with a fiber sealing material for preventing leakage of body fluid from the nostril, or a fiber sealing material for loading in the mouth, As a result, it is convenient to carry and the body can be treated quickly.

Fiber sealing material for preventing leakage of body fluids from the ear and nostrils is made of cotton, superabsorbent resin fibers, blends of cotton and superabsorbent resin fibers, and non-woven fabrics. What was shape | molded in this shape can be used suitably. It is preferable to provide two sealants for earplugs and two sealants for nasal plugs.
Also, the fiber sealing material for loading in the mouth is intended to be placed in the cheek to prevent leakage of bodily fluids and to form the bulge of the cheek in the direction close to the natural bulge. , Cotton and superabsorbent resin fiber blend, cloth or non-woven fabric such as superabsorbent resin fiber, or non-woven fabric of cotton and superabsorbent resin fiber, or a sandwich of these single component members in any layer structure The sealing material which consists of the member laminated | stacked on can be used suitably.

  As mentioned above, although each aspect of the corpse treatment apparatus suitable for injection | pouring of the bodily fluid leakage prevention agent of this invention was demonstrated referring an accompanying drawing, the oil jelly-like bodily fluid leakage prevention agent of this invention is a well-known injector. Needless to say, the present invention is not limited to the above-described embodiments, and it can be injected and loaded into a body cavity such as the mouth, nose, ear, anus, or vagina of a woman and sealed.

  Examples and test examples in which the effects of the body fluid leakage preventing agent of the present invention are specifically confirmed are shown below, but the present invention is of course not limited to the following examples.

Examples 1 to 5 and Comparative Example 1
Oil jelly-like body fluid leakage preventing agents in which superabsorbent resin powders were uniformly dispersed were prepared at the formulations and blending ratios shown in Table 1 (Examples 1 to 5). For comparison, the superabsorbent resin powder is uniformly dispersed in a solution in which an acrylic acid polymer (carboxyvinyl polymer / alkali neutralizer) as a gelling agent is dissolved in ethylene glycol, which is an alcohol solvent. A body fluid leakage preventing agent was prepared (Comparative Example 1).
The water absorption rates of the body fluid leakage preventing agents thus prepared were compared by the following test methods.

Test example 1 (water absorption rate test of sample)
Test method:
1 g of a test sample was weighed into a 100 ml beaker, and then 80 ml of ion-exchanged water (20 ° C.) was gently injected, and the time until all the ion-exchanged water became jelly was measured.
The test results are also shown in Table 1.

  As is clear from the results shown in Table 1 above, in the case of Comparative Example 1 using an alcohol base, it takes a long time to prepare the body fluid leakage preventing agent, indicating that workability is poor. On the other hand, in Examples 1 to 5 of the present invention, even when the amount of the superabsorbent resin powder added is increased, the dispersion stability when left for a long time is excellent, and slightly compared with Comparative Example 1. Despite the increase in the amount of the superabsorbent resin powder added, the time until the entire ion-exchanged water was made into a jelly could be greatly shortened. From this, it can be seen that the body fluid leakage preventing agent of the present invention is optimal as a body fluid leakage preventing agent that quickly solidifies into a solid jelly having no fluidity to prevent body fluid leakage.

The polyoxyethylene dimethyl ether (Sunfine DM-200) used in each of the above examples has no viscosity and is a smooth liquid, so it can be easily mixed with water, and the superabsorbent resin powder can easily absorb water. It seems to be. However, since there is a tendency that the solvent comes out first when injected with an injector and it is difficult to inject it, PEG-200, Sannonic SS as in Examples 2 and 3 are used to make the composition viscous. It is preferable to add -120 or a thickener such as ethyl cellulose as in Examples 4 and 5.
Sannonic SS-120 (polyoxyethylene alkyl ether) dissolves ethyl cellulose (about 49% ethoxy group) and thickens. As the degree of substitution of ethoxy groups increases, ethyl cellulose dissolves in nonpolar solvents and becomes difficult to dissolve in polar solvents. Usually, those in which 43 to 50% of ethoxy groups are substituted are soluble in nonpolar solvents. As in Example 4 above, when 1% of ethyl cellulose is added, an ideal oil jelly-like body fluid leakage preventing agent having a high water absorption rate, good stability, and no separation even when left for a long time can be prepared. . However, when a large amount of ethyl cellulose is added, the water absorption rate tends to deteriorate. Therefore, in the case of the formulation as in each of the above Examples, the addition amount of ethyl cellulose is preferably 0.2 to 5%, particularly 0.5 to 1. .5% is desirable. In the case of a thickened solution obtained by dissolving ethyl cellulose in Sannonic SS-120, it is difficult to separate into a jelly when a polar solvent is added. Therefore, in such a combination, the addition of a polar solvent should be avoided. Is preferable. Further, as in Example 5, when a nonionic surfactant is added to a solution obtained by dissolving ethyl cellulose in Sannonic SS-120 and increasing the viscosity, the water absorption rate is slightly slowed, but the slippage of the jelly-like material is improved and the body cavity is improved. Smooth filling and filling.

Examples 6-10
An oil jelly-like body fluid leakage preventing agent in which the superabsorbent resin powder was uniformly dispersed was prepared with the formulation and mixing ratio shown in Table 2.
The water absorption rate of the body fluid leakage preventing agent thus prepared was tested in the same manner as in Test Example 1. The test results are also shown in Table 2.

  In the said Examples 6-10, the Viscostar 50K (powder) added as a thickener melt | dissolves in an ether solvent (Sunfine DM-200), thickens, and turns into a viscous liquid. Further, Viscostar 50K (powder) is easily dissolved in water and becomes a viscous liquid. Therefore, Viscostar 50K (powder) is a very excellent raw material as a thickener for ether solvents. However, when a large amount is added to the prescription of the oil jelly-like product, it tends to be agglomerated and it becomes difficult to inject with an injector, so in the case of the prescription as in the above example, Viscostar 50K (powder) Is preferably 0.1 to 6%, particularly preferably 0.1 to 2%. Moreover, when the addition amount of the heat-plastic nonionic water-absorbing resin is increased as in Examples 8 and 9, the viscosity of the oil jelly-like material is improved and the filling property to the injector is improved. However, when a large amount of the heat-plastic nonionic water-absorbing resin is added, the viscosity of the oil jelly-like product increases, but the water absorption rate tends to deteriorate little by little, so it is not preferable to add a large amount. Further, as in Example 9, when a small amount of PEG-200 is added, the oil jelly-like product becomes soft and the filling becomes smooth. However, since it becomes a viscous liquid, there is a tendency for the water absorption speed to deteriorate, so it is not preferable to add a large amount. Similarly, as in Example 10, when a nonionic surfactant (Sannonic SS-120) is added, the water absorption rate tends to deteriorate, so it is not preferable to add a large amount.

Examples 11-17
An oil jelly-like body fluid leakage preventing agent in which the superabsorbent resin powder was uniformly dispersed was prepared with the formulation and mixing ratio shown in Table 3. The obtained oil jelly-like body fluid leakage preventing agent was excellent in water absorption rate.

Test example 2 (exothermic temperature measurement test of test material)
Test method:
10 g of each raw material shown in Table 4 was weighed into a 30 ml beaker, and then the exothermic temperature of the mixed solution when 8 g of ion-exchanged water was injected was measured under the following conditions.
Measuring instrument: Temperature sensor for liquid of DATA COLLECTOR manufactured by Anritsu Keiki Co., Ltd.
Room temperature at the time of measurement: 22.3 ° C.
The test results are also shown in Table 4.

  As shown in Table 4 above, in the case of PEG200, which is a liquid nonionic surfactant, heat was generated immediately when mixed with water, it became quickly soluble in water, and the temperature level could be maintained for a certain period of time. In contrast, anhydrous glycerin, ethylene glycol, and ethyl alcohol, which are alcohol solvents, generate a slight amount of heat after being mixed with water, but the temperature level is quite low and the temperature level cannot be maintained. This indicates that PEG200, which is a liquid nonionic surfactant, is suitable for increasing the liquid absorption rate of the highly water-absorbent resin.

It is a schematic sectional drawing which shows the use condition of the conventional corpse treatment apparatus. 1 shows an embodiment of a corpse treatment apparatus suitable for injection of the bodily fluid leakage preventing agent of the present invention, wherein (A) is a front view, (B) is a left side view, and (C) is a right side view. It is a longitudinal cross-sectional view along the center axis line of the corpse treatment apparatus shown in FIG. It is a cross-sectional view along the central axis of the corpse treatment apparatus shown in FIG. It is a longitudinal cross-sectional view which shows the insertion tube of the corpse treatment apparatus suitable for injection | pouring of the bodily fluid leakage prevention agent of this invention. The other embodiment of the corpse treatment apparatus suitable for injection | pouring of the bodily fluid leakage prevention agent of this invention is shown, (A) is a front view, (B) is a left view, (C) is a right view. It is a longitudinal cross-sectional view along the center axis line of the corpse treatment apparatus shown in FIG. It is a cross-sectional view along the central axis of the body treatment apparatus shown in FIG.

Explanation of symbols

1, 10, 10a Syringe 20, 20a Cylindrical body 21, 21a Cylindrical member 22, 22a Discharge port (discharge cylinder)
23 Locking portion 24 Projection portion 25, 25a Cover member 26 Gutter portion 27, 44 Stopper portion 28 Tongue piece 29, 29a Protective cap 30 Piston 31 Piston rod 32 Circular flange portion 33 Flange portion 34 Gasket 35 Disc-shaped portion 40 Insertion Tube 42 Opening part 43 Connection part X Fluid leakage preventive agent Y Fibrous filler A Nostril B Throat part C Tongue D Trachea E Esophageal

Claims (5)

  At least one solvent (A) selected from the group consisting of hydrophilic ethers and esters, polyalkylene oxide-based thermoplastic nonionic water-absorbing resin, acrylic acid copolymer carboxyvinyl polymer, acrylic acid Copolymer carboxyvinyl polymer / alkaline neutralizer, lipophilic smectite, synthetic hectorite, natural hectorite, and at least one dispersion stabilizer (B) and / or thickener selected from the group consisting of bentonite A corporal body fluid leakage preventive agent characterized in that the superabsorbent resin powder (D) is dispersed in a viscous liquid base containing (C).   The body fluid leakage preventing agent according to claim 1, wherein the solvent (A) is at least one selected from the group consisting of polyoxyethylene dimethyl ether and polyoxyethylene fatty acid diester.   The body fluid leakage preventing agent according to claim 1 or 2, wherein the dispersion stabilizer (B) is a polyalkylene oxide-based thermoplastic nonionic water-absorbing resin.   The body fluid according to any one of claims 1 to 3, wherein the thickener (C) is at least one selected from the group consisting of urethane resin, polyvinyl ether, ethyl cellulose, and polyethylene oxide. Leakage prevention agent.   Furthermore, it contains at least one selected from the group consisting of a liquid nonionic surfactant (E) that generates heat when mixed with water and an alcohol-based organic solvent (F) soluble in water. The bodily fluid leakage preventive agent according to any one of 1 to 4.

Images